Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel therapies for myelofibrosis.

Leukemia & lymphoma - 1 Jan 2015

Stein Brady L, Cervantes Francisco, Giles Francis, Harrison Claire N, Verstovsek Srdan

Abstract excerpt

Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the JAK2(V617F) mutation. Therefore, all symptomatic MF patients may potentially derive benefit from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance
Share to Janus Kinases
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Promyelocytic Leukemia Protein

Share to Protein Kinase Inhibitors

Share to STAT Transcription Factors

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25860240
DOI: 10.3109/10428194.2015.1037762
PMCID: PMC5008691

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel therapies for myelofibrosis.PMID 25860240Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Biology and therapeutic targeting of molecular mechanisms in MPNs.Semantic proximity Read ↗

Myelofibrosis biology and contemporary management.Semantic proximity Read ↗

Emerging targeted therapies in myelofibrosis.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentSemantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

Therapeutic potential of JAK2 inhibitorsSemantic proximity Read ↗

How I treat myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.